Lupus erythematosus with antiphospholipid syndrome and erythema multiforme-like lesions

British Journal of Dermatology

Volumn 141, Issue 4, 1999, Pages 720-724

  Marzano, A V ^a   Berti, E ^a   Gasparini, G ^a   Caputo, R ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Antiphospholipid syndrome; Erythema multiforme; Lupus erythematosus; Multiple autoimmune syndromes; Rowell's syndrome

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; LUPUS ANTICOAGULANT; METHYLPREDNISOLONE; PHOSPHOLIPID ANTIBODY; PREDNISONE;

ADULT; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; ERYTHEMA MULTIFORME; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS; PRIORITY JOURNAL; RASH; ROWELL SYNDROME; SKIN BIOPSY; SKIN MANIFESTATION; SYNDROME DELINEATION;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ERYTHEMA MULTIFORME; FACIAL DERMATOSES; FEMALE; HUMANS; LEG DERMATOSES; LUPUS ERYTHEMATOSUS, SYSTEMIC; SKIN;

EID: 0032692575     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.03118.x     Document Type: Article

References (31)

1. 1 Pedro SD, Dahl MV. Direct immunofluorescence of bullous systemic lupus erythematosus. Arch Dermatol 1973; 107: 118-20.
2. 2 Scholtz M. Lupus erythematosus acutus disseminatus haemorrhagicus. Arch Dermatol Syphilol 1922; 6: 466-75.
3. 3 Lewis-Jones MS, Evans S, Thompson CM. Erythema multiforme occurring in association with lupus erythematosus during therapy with doxycycline. Clin Exp Dermatol 1988; 13: 245-7.
4. 4 Rowell NR, Beck SJ. Anderson JR. Lupus erythematosus and erythema multiforme-like lesions. Arch Dermatol 1963; 88: 176-80.
5. 5 Humbert P, Dupond JL. Les syndromes autoimmuns multiples. Ann Med Intern 1988; 139: 159-68.
6. 6 Humbert P, Dupond JL, Vuitton D, Agache P. Dermatological autoimmune diseases and the multiple autoimmune syndromes. Acta Derm Venereol (Stockh) 1989; 148 (Suppl.): 1-8.
7. 7 Corbellino M, Poirel L, Bestetti G et al. Restricted tissue distribution of extralesional Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS patients with Kaposi's sarcoma. AIDS Res Hum Retroviruses 1996; 12: 651-7.
8. 8 Jablonska S, Blaszyck M, Chorzelski T. Syndrome de Rowell: lupus erythemateux avec des lésions coexistantes de type erythema polymorphe bulleux. Med Hyg 1972; 1026: 1390-3.
9. 9 Fabbri P, Panconesi E, Syndrome de Rowell; étude clinique et immunopathologique de deux cas. Ann Dermatol Syphilol 1975; 102: 405-6.
10. 10 Lawrence CM, Marshall TL, Byrne JPH. Lupus erythematosus associated with erythema multiforme-like lesions in identical twins. Br J Dermatol 1982; 107: 349-56.
11. 11 Heyl T, Meyer T. Lupus erythematosus with erythema multiforme (Rowell's syndrome). South Afr Med J 1984; 65: 568-9.
12. 12 Crickx B, Crickx L, Vissuzaine C et al. Chronic lupus erythematosus with erythema multiforme-like lesions (Rowell's syndrome). Ann Dermatol Venereol 1985; 112: 705-6.
13. 13 Parodi A, Drago EF, Varaldo G et al. Rowell's syndrome: report of a case. J Am Acad Dermatol 1989; 21: 374-7.
14. 14 Berenbein BA, Shakhnes IE. Rowell's syndrome. Vest Dermatol Venereol 1990; 1: 60-2.
15. 15 Fitzgerald EA, Purcell SM, Kantor GR, Goldman HM. Rowell's syndrome: report of a case. J Am Acad Dermatol 1996; 35: 801-3.
16. 16 Fiallo P, Tagliapietra AG, Santoro G, Venturino E. Rowell's syndrome. Int J Dermatol 1995; 34: 635-6.
17. 17 Herrera-Esparza R, Halim HY, Provost TT, Diaz LA. A sensitive and specific assay to detect Ro (SS-A) and La (SS-B) antibodies. J Invest Dermatol 1986; 86: 217-21.
18. 18 Drago F, Romagnoli M, Loi A, Rebora A. Epstein-Barr virus-related persistent erythema multiforme in chronic fatigue syndrome. Arch Dermatol 1992; 128: 217-22.
19. 19 Drago F, Parodi A, Rebora A. Persistent erythema multiforme: report of two new cases and review of literature. J Am Acad Dermatol 1995; 33: 366-9.
20. 20 Leigh IM, Mowbray JF, Levene GM et al. Recurrent and continuous erythema multiforme: a clinical and immunological study. Clin Exp Dermatol 1985; 10: 58-67.
21. 21 Schofield JK, Tatnall FM, Leigh IM. Recurrent erythema multiforme: clinical features and treatment in a large series of patients. Br J Dermatol 1993; 128: 542-5.
22. 22 Lerner MR, Andrews NC, Miller G, Steitz JA. Two small RMAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 1981; 78: 805-9.
23. 23 Ngou J, Graafland H, Segondy M. Antibodies against polypeptides of purified Epstein-Barr virus in sera from patients with connective tissue diseases. J Autoimmun 1992; 5: 243 9.
24. 24 James JA, Kaufman KM, Farris AD et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus, J Clin Invest 1997; 100: 3019-26.
25. 25 Khamashta MA, Hughes GRV. Antiphospholipid syndrome. Br Med J 1993; 307: 883-4.
26. 26 Stephens CJM. The antiphospholipid syndrome. Clinical correlations, cutaneous features, mechanisms of thrombosis and treatment of patients with the lupus anticoagulant and anticardiolipin antibodies. Br J Dermatol 1991; 125: 199-210.
27. 27 Frances C, Tribout B, Boisnic S et al. Cutaneous necrosis associated with the lupus anticoagulant. Dermatologica 1989; 178: 194 201.
28. 28 O'Neill A, Gatenby PA, McGaw B et al. Widespread cutaneous necrosis associated with cardiolipin antibodies. J Am Acad Dermatol 1990; 22: 356-9.
29. 29 Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-98.
30. 30 Boxer M, Ellman L, Carvalho A. The lupus anticoagulant. Arthritis Rheum 1976; 19: 1244-8.
31. 31 Schleider MA, Nachman RL. Jaffee EA et al. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509.